Artio Medical Closes $28M in Additional Series A Financing

Artio Medical, Inc., the medical device company that is developing innovative products for the peripheral vascular, neurovascular, and cardiology markets, announced this week the closing of $28 million in oversubscribed Series A2 and Series A3 financing. This brings the total amount raised to date to $74 million.

Artio is a Serra Capital III and Serra Capital III SBIC company.

Artio Medical’s Amplifi Vein Dilation System Demonstrates Encouraging Results

Artio Medical, Inc., a medical device company developing innovative products for the peripheral vascular, neurovascular, and structural heart markets, today announced that full results from its first-in-human (FIH) clinical study of the Amplifi™ Vein Dilation System were presented at the 2021 VEITH Symposium by Surendra Shenoy, MD-PhD, an Associate Professor of Surgery at the Washington University School of Medicine at Barnes-Jewish Hospital in St. Louis, Missouri. 

"Data from the first five patients treated with the Amplifi System demonstrated more than a doubling of forearm and upper arm cephalic vein diameters following a mean treatment period of 8.6 days. We were able to successfully create an arteriovenous fistula (AVF) using treated veins in all patients and observed rapid and robust AVF maturation," commented Dr. Shenoy. "This data is very encouraging and I believe this technology has the potential to offer a much-needed solution for increasing AVF suitability and reducing maturation failure."

Artio Medical is a Serra Capital III and Serra Capital III SBIC company. To view the full article, follow here.